Fig 1.
Two days of treatment with ST-246 at 100 mg/kg dose starting 24 h postchallenge with IHD-J-Luc VACV was required to protect 100% of BALB/c mice from lethality. (A to F) Lethality outcome and bioluminescence measurements in the internal organs of BALB/c mice infected with recombinant IHD-J-Luc VACV. BALB/c mice were infected intranasally with IHD-J-Luc VACV at 105 PFU. Starting 24 h postchallenge, mice received daily treatments with vehicle alone for 5 days (black circles) or with ST-246 for 1 day (purple open circle), 2 days (blue diamond), 3 days (green triangle), or for 5 days (red square) (A to F) at 100 mg/kg (A, C to F) or at 30 mg/kg (B). Mice were observed for survival (A and B) and were subjected to whole-body bioimaging (C to F). Total fluxes in the nasal cavity (B), lungs (D), liver (E), and spleen (F) were determined and used to calculate the mean total flux ± the standard deviation (SD) using a Student t test. Vehicle/1, 28 animals per group; vehicle/2, 18 animals per group; all ST-246-treated mice, 6 mice per group.